Call to arms: need for radiobiology in molecular radionuclide therapy
- 457 Downloads
Now is an extraordinarily exciting time for the multidisciplinary field of molecular radionuclide therapy (MRT) [1, 2, 3]. More patients than ever before are being treated with radiolabelled compounds, and an increasing number of pharmaceutical companies incorporate radiopharmaceuticals into their portfolios.
MRT allows specific irradiation of localised and disseminated disease, with potentially fewer side effects than external beam radiotherapy (EBRT). However, aside from obvious improvements in radiochemistry, radiopharmacy, and dosimetry of MRT agents, a better understanding of the radiobiology, i.e. of the biological effects of ionising radiation of MRT agents, is needed.
Radiobiology has been key in establishing optimal treatment regimens for EBRT whilst protecting healthy tissues. The paradigm of radiobiology is that tumour control probability and side effects are proportional to absorbed radiation dose; radiobiology is thus deeply connected with dosimetry. However,...
The authors would like to acknowledge Mark Konijnenberg, Emmanuel Deshayes, and Fijs van Leeuwen for their comments during preparation of this letter.
Compliance with ethical standards
Conflict of interest
Author ST declares that she has no conflict of interest. Author JN has an investigator-initiated project contract with Advanced Accelerator Applications, a Novartis company. Author AA declares that she has no conflict of interest. Author SB declares that she has no conflict of interest. Author MdJ has an investigator-initiated project contract with Advanced Accelerator Applications, a Novartis company. Author BC is a paid consultant for Molecular Targeted Radiopharmaceuticals. Author J-PP declares that he has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 7.European Association of Nuclear Medicine Internal Dosimetry Task Force Report, Treatment planning for molecular radiotherapy: potential and prospects. Flux G, Stokke C., editors. 2017.Google Scholar
- 8.European Council Directive. 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protections against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Off J Eur Union. 2014.Google Scholar